Central control of body weight and appetite

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 11 SUPPL. 1, 2008, Pages

  Woods, Stephen C ^a   D'Alessio, David A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; AMYLIN; APOLIPOPROTEIN A4; BOMBESIN; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; ENTEROSTATIN; GASTRIN RELEASING PEPTIDE; GHRELIN; GLICENTIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INSULIN; LEPTIN; NEUROMEDIN B; OXYNTOMODULIN; PEPTIDE YY; PLACEBO; PRAMLINTIDE;

BODY FAT; BODY WEIGHT; DRUG EFFICACY; ENERGY BALANCE; FOOD INTAKE; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SATIETY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

EID: 55849141253     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1630     Document Type: Review

References (243)

1. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000 Central nervous system control of food intake. Nature 404:661-671
2. Woods SC, Seeley RJ, Porte Jr D, Schwartz MW 1998 Signals that regulate food intake and energy homeostasis. Science 280:1378-1383
3. Woods SC 2005 Signals that influence food intake and body weight. Physiol Behav 86:709-716
4. Strubbe JH, Woods SC 2004 The timing of meals. Psychol Rev 111:128-141
5. Woods SC 1991 The eating paradox: how we tolerate food. Psychol Rev 98:488-505
6. Woods SC, Ramsay DS 2007 Homeostasis: beyond Curt Richter. Appetite 49:388-398
7. Moran TH, Kinzig KP 2004 Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol 286:G183-G188
8. Moran TH 2004 Gut peptides in the control of food intake: 30 years of ideas. Physiol Behav 82:175-180
9. Strader AD, Woods SC 2005 Gastrointestinal hormones and food intake. Gastroenterology 128:175-191
10. Polonsky KS, Given E, Carter V 1988 Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81:442-448
11. Teff KL, Townsend RR 2004 Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-peptide secretion in humans. J Clin Endocrinol Metab 89:5606-5613
12. Kaplan JM, Moran TH 2004 Gastrointestinal signaling in the control of food intake. In: Stricker EM, Woods SC, eds. Handbook of behavioral neurobiology. Neurobiology of food and fluid intake. Vol. 4, no. 2. New York: Kluwer Academic/Plenum Publishing; 273-303
13. Wren AM, Bloom SR 2007 Gut hormones and appetite control. Gastroenterology 132:2116-2130
14. Wren AM 2008 Gut and hormones and obesity. Front Horm Res 36:165-181
15. Smith GP, Gibbs J 1992 The development and proof of the cholecystokinin hypothesis of satiety. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, eds. Multiple cholecystokinin receptors in the CNS. Oxford, UK: Oxford University Press; 166-182
16. Chandra R, Liddle RA 2007 Cholecystokinin. Curr Opin Endocrinol Diabetes Obes 14:63-67
17. Grider JR 1994 Role of cholecystokinin in the regulation of gastrointestinal motility. J Nutr 124:1334S-1339S
18. Raybould HE 2007 Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol 7:570-574
19. Schwartz GJ, Moran TH, White WO, Ladenheim EE 1997 Relationships between gastric motility and gastric vagal afferent responses to CCK and GRP in rats differ. Am J Physiol 272:R1726-R1733
20. Edwards GL, Ladenheim EE, Ritter RC 1986 Dorsomedial hindbrain participation in cholecystokinin-induced satiety. Am J Physiol 251:R971-R977
21. Lorenz DN, Goldman SA 1982 Vagal mediation of the cholecystokinin satiety effect in rats. Physiol Behav 29:599-604
22. Moran TH, Shnayder L, Hostetler AM, McHugh PR 1988 Pylorectomy reduces the satiety action of cholecystokinin. Am J Physiol 255:R1059-R1063
23. Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ 1997 Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol 272:R1245-R1251
24. Berthoud HR, Earle T, Zheng H, Patterson LM, Phifer C 2001 Food-related gastrointestinal signals activate caudal brainstem neurons expressing both NMDA and AMPA receptors. Brain Res 915:143-154
25. Berthoud HR 2007 Interactions between the "cognitive" and "metabolic" brain in the control of food intake. Physiol Behav 91:486-498
26. Rinaman L 2004 Hindbrain contributions to anorexia. Am J Physiol Regul Integr Comp Physiol 287:R1035-R1036
27. Rinaman L 2007 Visceral sensory inputs to the endocrine hypothalamus. Front Neuroendocrinol 28:50-60
28. Rinaman L, Hoffman GE, Dohanics J, Le WW, Stricker EM, Verbalis JG 1995 Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats. J Comp Neurol 360:246-256
29. Beglinger C, Degen L, Matzinger D, D'Amato M, Drewe J 2001 Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol 280:R1149-R1154
30. Hewson G, Leighton GE, Hill RG, Hughes J 1988 The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of endogenous cholecystokinin. Br J Pharmacol 93:79-84
31. Reidelberger RD, O'Rourke MF 1989 Potent cholecystokinin antagonist L-364,718 stimulates food intake in rats. Am J Physiol 257:R1512-R1518
32. Crawley JN, Beinfeld MC 1983 Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302:703-706
33. West DB, Fey D, Woods SC 1984 Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 246:R776-R787
34. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB 1995 Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36:176-179
35. Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C 2004 Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 287:R562-R567
36. Lieverse RJ, Jansen JB, Masclee AA, Rovati LC, Lamers CB 1994 Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide. Gut 35:501-505
37. Degen L, Drewe J, Piccoli F, Grani K, Oesch S, Bunea R, D'Amato M, Beglinger C 2007 Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. Am J Physiol Regul Integr Comp Physiol 292:R1391-R1399
38. Funakoshi A, Miyasaka K, Matsumoto H, Yamamori S, Takiguchi S, Kataoka K, Takata Y, Matsusue K, Kono A, Shimokata H 2000 Gene structure of human cholecystokinin (CCK) type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. FEBS Lett 466:264-266
39. Holst JJ 1997 Enteroglucagon. Annu Rev Physiol 59:257-271
40. Dube PE, Brubaker PL 2004 Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res 36:755-760
41. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
42. Giralt M, Vergara P 1999 Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 44:322-329
43. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
44. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24
45. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA 2003 Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-1779
46. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R 2005 Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554-3563
47. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, Colom A, Rastrelli S, Delzenne NM, Drucker DJ, Seeley RJ, Burcelin R 2008 Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose-sensing. Diabetes, 57:2603-2612
48. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA 2007 Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973
49. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP 1996 Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856
50. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996 A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature 379:69-72
51. Donahey JC, van Dijk G, Woods SC, Seeley RJ 1998 Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res 779:75-83
52. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM 1998 Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68:525-530
53. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C 1999 Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81-86
54. van Dijk G, Thiele TE, Donahey JCK, Campfield LA, Smith FJ, Burn P, Bernstein IL, Woods SC, Seeley RJ 1996 Central infusion of leptin and GLP-1 (7-36) amide differentially stimulate c-Fos-like immunoreactivity in the rat brain. Am J Physiol 271:R1096-R1100
55. Shughrue PJ, Lane MV, Merchenthaler I 1996 Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159-5162
56. Navarro M, Rodriquez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blazquez E 1996 Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982-1991
57. Kinzig KP, D'Alessio DA, Seeley RJ 2002 The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22:10470-10476
58. Larsen PJ, Tang-Christensen M, Jessop DS 1997 Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445-4455
59. McMahon LR, Wellman PJ 1997 Decreased intake of a liquid diet in non-food-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol Biochem Behav 58:673-677
60. McMahon LR, Wellman PJ 1997 PVN infusion of GLP-1(7-36) amide suppresses feeding and drinking but does not induce conditioned taste aversions or alter locomotion in rats. Am J Physiol 274:R23-R29
61. Seeley RJ, Blake K, Rushing PA, Benoit SC, Eng J, Woods SC, D'Alessio D 2000 The role of CNSGLP-1-(7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20:1616-1621
62. Kinzig KP, D'Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueredo HF, Murphy EK, Seeley RJ 2003 CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23:6163-6170
63. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM 1999 Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311
64. Toft-Nielsen MB, Madsbad S, Holst JJ 1999 Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143
65. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C 1999 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544
66. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M 2002 Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol 282:G424-G431
67. Kastin AJ, Akerstrom V, Pan W 2002 Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18:7-14
68. Ahren B 2007 GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diab Rep 7:340-347
69. Madsbad S, Krarup T, Deacon CF, Holst JJ 2008 Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 11:491-499
70. Mafong DD, Henry RR 2008 Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 10:55-60
71. Flatt PR, Bailey CJ, Green BD 2008 Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 13:3648-3660
72. Pei Z 2008 From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Devel 11:512-532
73. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K 2007 Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493
74. Kirkegaard P, Moody AJ, Holst JJ, Loud FB, Olsen PS, Christiansen J 1982 Glicentin inhibits gastric acid secretion in the rat. Nature 297:156-157
75. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR 2001 Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244-4250
76. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
77. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR 2006 Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30:1729-1736
78. Wynne K, Bloom SR 2006 The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2:612-620
79. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR 2002 Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283:E1173-E1177
80. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR 2003 Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696-4701
81. Drucker DJ 1999 Glucagon-like peptide 2. Trends Endocrinol Metab 10:153-156
82. Jeppesen PB 2003 Clinical significance of GLP-2 in short-bowel syndrome. J Nutr 133:3721-3724
83. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV 1986 Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119:1467-1475
84. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N 2000 The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802-807
85. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartmann B, Holst JJ, Hellstrom PM 2003 Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116:21-25
86. Geary N 1998 Glucagon and the control of meal size. In: Smith GP, ed. Satiation. From gut to brain. New York: Oxford University Press; 164-197
87. Woods SC, Lutz TA, Geary N, Langhans W 2006 Pancreatic signals controlling food intake; insulin, glucagon, and amylin. Philos Trans R Soc Lond B Biol Sci 361:1219-1235
88. Woods SC, Lotter EC, McKay LD, Porte Jr D 1979 Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282:503-505
89. Geary N, Le Sauter J, Noh U 1993 Glucagon acts in the liver to control spontaneous meal size in rats. Am J Physiol 264:R116-R122
90. Langhans W, Zieger U, Scharrer E, Geary N 1982 Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science 218:894-896
91. LeSauter J, Noh U, Geary N 1991 Hepatic portal infusion of glucagon antibodies increases spontaneous meal size in rats. Am J Physiol 261:R162-R165
92. Adrian TE, Bacarese-Hamilton AJ, Smith HA, Chohan P, Manolas KJ, Bloom SR 1987 Distribution and postprandial release of porcine peptide YY. J Endocrinol 113:11-14
93. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve Jr JR 1994 Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151-159
94. Mentlein R, Dahms P, Grandt D, Kruger R 1993 Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133-144
95. Larhammar D 1996 Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65:165-174
96. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR 2002 Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650 -654
97. Vincent RP, le Roux CW 2008 The satiety hormone peptide YY as a regulator of appetite. J Clin Pathol 61:548-552
98. Lin HC, Zhao XT, Wang L, Wong H 1996 Fat-induced ileal brake in the dog depends on peptide YY. Gastroenterology 110:1491-1495
99. Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, Ruggeri E, Tosetti C, Poggioli G, Morselli Labate AM, Monetti N, Gozzetti G, Barbara L, Go VLW 1993 Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology 105:733-739
100. Pfluger PT, Kampe J, Castaneda TR, Vahl T, D'Alessio DA, Kruthaupt T, Benoit SC, Cuntz U, Rochlitz HJ, Moehlig M, Pfeiffer AF, Koebnick C, Weickert MO, Otto B, Spranger J, Tschop MH 2007 Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 92:583-588
101. Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee YC, Bloom SR, Misiewicz JJ, Silk DB 1984 The ileal brake - inhibition of jejunal motility after ileal fat perfusion in man. Gut 25:365-374
102. Nonaka N, Shioda S, Niehoff ML, Banks WA 2003 Characterization of blood-brain barrier permeability to PYY3-36 in mouse. J Pharmacol Exp Ther 306:948-953
103. Batterham RL, Bloom SR 2003 The gut hormone peptide YY regulates appetite. Ann NY Acad Sci 994:162-168
104. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C 2005 Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129:1430-1436
105. le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR 2006 Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147:3-8
106. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR 2003 Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948
107. Stock S, Leichner P, Wong AC, Ghatei MA, Kieffer TJ, Bloom SR, Chanoine JP 2005 Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 90:2161-2168
108. Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt J 2006 Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int J Obes (Lond) 30:453-459
109. Ahituv N, Kavaslar N, Schackwitz W, Ustaszewska A, Collier JM, Hebert S, Doelle H, Dent R, Pennacchio LA, McPherson R 2006 A PYY Q62P variant linked to human obesity. Hum Mol Genet 15:387-391
110. Tso P, Liu M, Kalogeris TJ, Thomson AB 2001 The role of apolipoprotein A-IV in the regulation of food intake. Annu Rev Nutr 21:231-254
111. Liu M, Doi T, Shen L, Woods SC, Seeley RJ, Zheng S, Jackman A, Tso P 2001 Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. Am J Physiol 280:R1382-R1387
112. Fujimoto K, Fukagawa K, Sakata T, Tso P 1993 Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 91:1830-1833
113. Fujimoto K, Machidori H, Iwakiri R, Yamamoto K, Fujisaki J, Sakata T, Tso P 1993 Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity in rats. Brain Res 608:233-237
114. Lo CM, Zhang DM, Pearson K, Ma L, Sun W, Sakai RR, Davidson WS, Liu M, Raybould HE, Woods SC, Tso P 2007 Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am J Physiol Regul Integr Comp Physiol 293:R1490-R1494
115. Liu M, Shen L, Doi T, Woods SC, Seeley RJ, Tso P 2003 Neuropeptide Y and lipid increase apolipoprotein AIV gene expression in rat hypothalamus. Brain Res 971:232-238
116. Tso P, Liu M 2004 Apolipoprotein A-IV, food intake, and obesity. Physiol Behav 83:631-643
117. Okada S, York DA, Bray GA, Erlanson-Albertsson C 1991 Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectively reduces fat intake. Physiol Behav 49:1185-1189
118. Shargill NS, Tsuji S, Bray GA, Erlanson-Albertsson C 1991 Enterostatin suppresses food intake following injection into the third ventricle of rats. Brain Res 544:137-140
119. Mei J, Erlanson-Albertsson C 1992 Effect of enterostatin given intravenously and intracerebroventricularly on high-fat feeding in rats. Regul Pept 41:209-218
120. Okada S, York DA, Bray GA, Mei J, Erlanson-Albertsson C 1992 Differential inhibition of fat intake in two strains of rat by the peptide enterostatin. Am J Physiol 262:R1111-R1116
121. Muurahainen NE, Kissileff HR, Pi-Sunyer FX 1993 Intravenous infusion of bombesin reduces food intake in humans. Am J Physiol 264:R350-R354
122. Ladenheim EE, Wirth KE, Moran TH 1996 Receptor subtype mediation of feeding suppression by bombesin-like peptides. Pharmacol Biochem Behav 54:705-711
123. Stein LJ, Woods SC 1982 Gastrin releasing peptide reduces meal size in rats. Peptides 3:833-835
124. Ladenheim EE, Hampton LL, Whitney AC, White WO, Battey JF, Moran TH 2002 Disruptions in feeding and body weight control in gastrin-releasing peptide receptor deficient mice. J Endocrinol 174:273-281
125. Stuckey JA, Gibbs J, Smith GP 1985 Neural disconnection of gut from brain blocks bombesin-induced satiety. Peptides 6:1249-1252
126. Rushing PA, Henderson RP, Gibbs J 1998 Prolongation of the postprandial intermeal interval by gastrin-releasing peptide 1-27 in spontaneously feeding rats. Peptides 19:175-177
127. Lieverse RJ, Jansen JB, van de Zwan A, Samson L, Masclee AA, Rovati LC, Lamers CB 1993 Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanism. J Clin Endocrinol Metab 76:1495-1498
128. Gutzwiller JP, Drewe J, Hildebrand P, Rossi L, Lauper JZ, Beglinger C 1994 Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology 106:1168-1173
129. Hildebrand P, Lehmann FS, Ketterer S, Christ AD, Stingelin T, Beltinger J, Gibbons AH, Coy DH, Calam J, Larsen F, Beglinger C 2001 Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist. Gut 49:23-28
130. Degen LP, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, Larsen F, Beglinger C, Hildebrand P 2001 Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transit. Gastroenterology 120:361-368
131. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G 1997 Amylin: history and overview. Diabet Med 14(Suppl 2):S9-S13
132. Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa SJ, Fischer JE 1991 Anorexia following the intrahypothalamic administration of amylin. Brain Res 539:352-354
133. Lutz TA 2006 Amylinergic control of food intake. Physiol Behav 89:465-471
134. Lutz TA, Del Prete E, Scharrer E 1994 Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 55:891-895
135. Lutz TA, Geary N, Szabady MM, Del Prete E, Scharrer E 1995 Amylin decreases meal size in rats. Physiol Behav 58:1197-1202
136. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC 2000 Amylin: a novel action in the brain to reduce body weight. Endocrinology 141:850-853
137. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL, Woods SC 2001 Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142:5035
138. Martinez A, Kapas S, Miller MJ, Ward Y, Cuttitta F 2000 Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β-cells. Endocrinology 141:406-411
139. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM 2003 Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 278:3293-3297
140. Lutz TA, Senn M, Althaus J, Del Prete E, Ehrensperger F, Scharrer E 1998 Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19:309-317
141. Rushing PA, Lutz TA, Seeley RJ, Woods SC 2000 Amylin and insulin interact to reduce food intake in rats. Horm Metab Res 32:62-65
142. Mollet A, Meier S, Grabler V, Gilg S, Scharrer E, Lutz TA 2003 Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin. Peptides 24:91-98
143. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG 2002 A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730
144. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG 2003 Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26:784-790
145. Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschop MH 2007 Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 3:705-712
146. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS 2001 A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714-1719
147. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337-345
148. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR 2001 Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540-2547
149. Tschöp M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908-913
150. Drazen DL, Vahl TP, D'Alessio DA, Seeley RJ, Woods SC 2006 Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 147:23-30
151. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS 2002 Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8:643-644
152. Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL 2003 The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649-661
153. Lawrence CB, Snape AC, Baudoin FM, Luckman SM 2002 Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 143:155-162
154. Cummings DE 2006 Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 89:71-84
155. Traebert M, Riediger T, Whitebread S, Scharrer E, Schmid HA 2002 Ghrelin acts on leptin-responsive neurones in the rat arcuate nucleus. J Neuroendocrinol 14:580-586
156. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M 2002 The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120-1128
157. Arnold M, Mura A, Langhans W, Geary N 2006 Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J Neurosci 26:11052-11060
158. Adolph EF 1947 Urges to eat and drink in rats. Am J Physiol 151:110-125
159. Janowitz HD, Grossman MI 1949 Effect of variations in nutritive density of food in dogs and rats. Am J Physiol 158:184-193
160. Woods SC, Strubbe JH 1994 The psychobiology of meals. Psychon Bull Rev 1:141-155
161. McLaughlin CL, Baile CA 1979 Cholecystokinin, amphetamine and diazepam and feeding in lean and obese Zucker rats. Pharmacol Biochem Behav 10:87-93
162. Niederau C, Meereis-Schwanke K, Klonowski-Stumpe H, Herberg L 1997 CCK resistance in Zucker obese versus lean rats. Regul Pept 70:97-104
163. Kulkosky PJ, Breckenridge C, Krinsky R, Woods SC 1976 Satiety elicited by the C-terminal octapeptide of cholecystokinin-pancreozymin in normal and VMH-lesioned rats. Behav Biol 18:227-234
164. Chandler PC, Wauford PK, Oswald KD, Maldonado CR, Hagan MM 2004 Change in CCK-8 response after diet-induced obesity and MC3/4-receptor blockade. Peptides 25:299-306
165. Strohmayer AJ, Smith GP 1981 Cholecystokinin inhibits food intake in genetically obese (C57BL/6j-ob) mice. Peptides 2:39-43
166. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP 1982 C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 29:627-630
167. Williams DL, Baskin DG, Schwartz MW 2006 Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55:3387-3393
168. West DB, Greenwood MRC, Marshall KA, Woods SC 1987 Lithium chloride, cholecystokinin and meal patterns: evidence the cholecystokinin suppresses meal size in rats without causing malaise. Appetite 8:221-227
169. West DB, Williams RH, Braget DJ, Woods SC 1982 Bombesin reduces food intake of normal and hypothalamically obese rats and lowers body weight when given chronically. Peptides 3:61-67
170. D'Alessio DA, Vahl TP 2004 Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 286:E882-E890
171. D'Alessio DA, Vahl TP 2005 Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. Curr Diab Rep 5:346-352
172. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME 2007 Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29:139-153
173. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D 2005 Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 7:467-477
174. Banks WA 2006 The blood-brain barrier as a regulatory interface in the gut-brain axes. Physiol Behav 89:472-476
175. Woods SC, Seeley RJ, Baskin DG, Schwartz MW 2003 Insulin and the bloodbrain barrier. Curr Pharm Des 9:795-800
176. Benoit SC, Clegg DJ, Seeley RJ, Woods SC 2004 Insulin and leptin as adiposity signals. Recent Prog Horm Res 59:267-285
177. Friedman JM 2002 The function of leptin in nutrition, weight, and physiology. Nutr Rev 60:S1-S14; discussion S68- 84:85-87
178. Seeley RJ, Woods SC 2003 Monitoring of stored and available fuel by the CNS: implications for obesity. Nat Rev Neurosci 4:901-909
179. Grossman SP 1986 The role of glucose, insulin and glucagon in the regulation of food intake and body weight. Neurosci Biobehav Rev 10:295-315
180. Langhans W 1996 Metabolic and glucostatic control of feeding. Proc Nutr Soc 55:497-515
181. Lotter EC, Woods SC 1977 Injections of insulin and changes of body weight. Physiol Behav 18:293-297
182. Nicolaidis S, Rowland N 1976 Metering of intravenous versus oral nutrients and regulation of energy balance. Am J Physiol 231:661-668
183. Vanderweele DA, Haraczkiewicz E, Van Itallie TB 1982 Elevated insulin and satiety in obese and normal weight rats. Appetite 3:99-109
184. Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W 2004 Intranasal insulin reduces body fat in men but not in women. Diabetes 53:3024-3029
185. Hallschmid M, Benedict C, Born J, Fehm HL, Kern W 2004 Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiol Behav 83:55-64
186. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS 2006 Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 91:2605-2611
187. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P 2005 Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54:1994-2002
188. Israel PA, Park CR, Schwartz MW, Green PK, Sipols AJ, Woods SC, Porte Jr D, Figewicz DP 1993 Effect of diet-induced obesity and experimental hyperinsulinemia on insulin uptake into CSF of the rat. Brain Res Bull 30:571-575
189. Owen OE, Reichard GAJ, Boden G, Shuman C 1974 Comparative measurements of glucose, β-hydroxybutyrate, acetoacetate, and insulin in blood and cerebrospinal fluid during starvation. Metabolism 23:7-14
190. Stein LJ, Dorsa DM, Baskin DG, Figlewicz DP, Ikeda H, Frankmann SP, Greenwood MR, Porte Jr D, Woods SC 1983 Immunoreactive insulin levels are elevated in the cerebrospinal fluid of genetically obese Zucker rats. Endocrinology 113:2299-2301
191. Ikeda H, West DB, Pustek JJ, Figlewicz DP, Greenwood MRC, Porte Jr D, Woods SC 1986 Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats. Appetite 7:381-386
192. Woods SC, D'Alessio DA, Tso P, Rushing PA, Clegg DJ, Benoit SC, Gotoh K, Liu M, Seeley RJ 2004 Consumption of a high-fat diet alters the homeostatic regulation of energy balance. Physiol Behav 83:573-578
193. Cota D, Matter EK, Woods SC, Seeley RJ 2008 The role of hypothalamic mTORC1 signaling in diet-induced obesity. J Neurosci 28:7202-7208
194. Air EL, Strowski MZ, Benoit SC, Conarello SL, Salituro GM, Guan XM, Liu K, Woods SC, Zhang BB 2002 Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 8:179-183
195. Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vilella D, Diez MT, Pelaez F, Ruby C, Kendall RL, Mao X, Griffin P, Calaycay J, Zierath JR, Heck JV, Smith RG, Moller DE 1999 Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 284:974-977
196. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ 2001 The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25(Suppl 5):S63-S67
197. Peruzzo B, Pastor FE, Blazquez JL, Schobitz K, Pelaez B, Amat P, Rodriguez EM 2000 A second look at the barriers of the medial basal hypothalamus. Exp Brain Res 132:10-26
198. Ahima RS, Saper CB, Flier JS, Elmquist JK 2000 Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 21:263-307
199. Cone RD 2005 Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571-578
200. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB 2005 Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 493:63-71
201. Schwartz MW, Porte Jr D 2005 Diabetes, obesity, and the brain. Science 307:375-379
202. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW 2006 Central nervous system control of food intake and body weight. Nature 443:289-295
203. Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg DJ, Seeley RJ, Woods SC 2002 The catabolic action of insulin in the brain is mediated by melanocortins. J Neurosci 22:9048-9052
204. Seeley R, Yagaloff K, Fisher S, Burn P, Thiele T, van DG, Baskin D, Schwartz M 1997 Melanocortin receptors in leptin effects. Nature 390:349
205. Stanley BG, Leibowitz SF 1984 Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sciences 35:2635-2642
206. Clark JT, Kalra PS, Crowley WR, Kalra SP 1984 Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115:427-429
207. Corp ES, Melville LD, Greenberg D, Gibbs J, Smith GP 1990 Effect of fourth ventricular neuropeptide Y and peptide YY on ingestive and other behaviors. Am J Physiol 259:R317-R323
208. Zarjevski N, Cusin I, Vetter R, Rohner-Jeanrenaud F, Jeanrenaud B 1993 Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 133:1753-1758
209. Wilson BD, Ollmann MM, Barsh GS 1999 The role of agouti-related protein in regulating body weight. Mol Med Today 5:250-256
210. Vettor R, Zarjevski N, Cusin I, Johner-Jeanrenaud F, Jeanrenaud B 1994 Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37:1202-1208
211. Ollmann M, Wilson B, Yang Y, Kerns J, Chen Y, Gantz I, Barsh G 1997 Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135-138
212. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van der Ploeg HT, Woods SC, Seeley RJ 2000 Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am J Physiol 279:R47-R52
213. Hagan MM, Benoit SC, Rushing PA, Pritchard LM, Woods SC, Seeley RJ 2001 Immediate and prolonged patterns of agouti-related peptide-(83-132)- induced c-Fos activation in hypothalamic and extrahypothalamic sites. Endocrinology 142:1050-1056
214. Porte Jr D, Baskin DG, Schwartz MW 2005 Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 54:1264-1276
215. Schwartz MW 2006 Central nervous system regulation of food intake. Obesity (Silver Spring) 14(Suppl 1):1S-8S
216. Woods SC, Seeley RJ, Cota D 2008 Regulation of food intake through hypothalamic signaling networks involving mTOR. Annu Rev Nutr 28:295-311
217. Berthoud HR 2002 Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26:393-428
218. Levin BE 2006 Metabolic sensing neurons and the control of energy homeostasis. Physiol Behav 89:486-489
219. Lam TK, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, Aguilar-Bryan L, Schwartz GJ, Rossetti L 2005 Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 11:320-327
220. Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L 2002 Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51:271-275
221. Cota D, Proulx K, Woods SC, Seeley RJ 2006 Role of leucine in regulating food intake. Science 313:1236-1238
222. Cota D, Proulx K, Seeley RJ 2007 The role of CNS fuel sensing in energy and glucose regulation. Gastroenterology 132:2158-2168
223. Seeley RJ, York DA 2005 Fuel sensing and the central nervous system (CNS): implications for the regulation of energy balance and the treatment for obesity. Obes Rev 6:259-265
224. Fehm HL, Kern W, Peters A 2006 The selfish brain: competition for energy resources. Prog Brain Res 153:129-140
225. Berthoud HR 2006 Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance. Obesity (Silver Spring) 14(Suppl 5):197S-200S
226. Grill HJ, Kaplan JM 2002 The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 23:2-40
227. Schwartz GJ 2006 Integrative capacity of the caudal brainstem in the control of food intake. Philos Trans R Soc Lond B Biol Sci 361:1275-1280
228. Richard D, Huang Q, Timofeeva E 2000 The corticotropin-releasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord 24:S36-S39
229. Verbalis JG, Blackburn RE, Olson BR, Stricker EM 1993 Central oxytocin inhibition of food and salt ingestion: a mechanism for intake regulation of solute homeostasis. Regul Pept 45:149-154
230. Broberger C, De Lecea L, Sutcliffe JG, Hokfelt T 1998 Hypocretin/orexin-and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J Comp Neurol 402:460-474
231. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E 1996Arole for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380:243-247
232. Nahon JL 2006 The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. C R Biol 329:623-638; discussion 653-655
233. Sweet DC, Levine AS, Billington CJ, Kotz CM 1999 Feeding response to central orexins. Brain Res 821:535-538
234. Strubbe JH, van Dijk G 2002 The temporal organization of ingestive behaviour and its interaction with regulation of energy balance. Neurosci Biobehav Rev 26:485-498
235. Matson CA, Wiater MF, Kuijper JL, Weigle DS 1997 Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides 18:1275-1278
236. Matson CA, Ritter RC 1999 Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am J Physiol 276:R1038-R1045
237. Riedy CA, Chavez M, Figlewicz DP, Woods SC 1995 Central insulin enhances sensitivity to cholecystokinin. Physiol Behav 58:755-760
238. Emond M, Schwartz GJ, Ladenheim EE, Moran TH 1999 Central leptin modulates behavioral and neural responsivity to CCK. Am J Physiol 276:R1545-R1549
239. Figlewicz DP, Stein LJ, West D, Porte Jr D, Woods SC 1986 Intracisternal insulin alters sensitivity to CCK-induced meal suppression in baboons. Am J Physiol 250:R856-R860
240. Ladenheim EE, Emond M, Moran TH 2005 Leptin enhances feeding suppression and neural activation produced by systemically administered bombesin. Am J Physiol Regul Integr Comp Physiol 289:R473-R477
241. Morton GJ, Blevins JE, Williams DL, Niswender KD, Gelling RW, Rhodes CJ, Baskin DG, Schwartz MW 2005 Leptin action in the forebrain regulates the hindbrain response to satiety signals. J Clin Invest 115:703-710
242. McMinn JE, Sindelar DK, Havel PJ, Schwartz MW 2000 Leptin deficiency induced by fasting impairs the satiety response to cholecystokinin. Endocrinology 141:4442-4448
243. Grill HJ, Smith GP 1988 Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 254:R853-R856